NCT07548944 Observational Study to Investigate the Short-term Effects of Transcorneal Electrical Stimulation on Visual Performance
| NCT ID | NCT07548944 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Okuvision GmbH |
| Condition | Retinitis Pigmentosa (RP) |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2026-04-20 |
| Primary Completion | 2027-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2026-04-20 with a primary completion date of 2027-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Retinitis pigmentosa and similar degenerative diseases of the retina lead to progressive loss of vision. TES therapy with the CE-marked OkuStim® System is a treatment approved in the EU for slowing the progression of the disease. Patients increasingly report short-term subjective improvements in vision, which have not yet been systematically investigated. This exploratory study is conducted to determine whether these subjective short-term effects can be measured, and therefore also be quantified, by objective tests.
Eligibility Criteria
Inclusion Criteria: * Adult patients (≥ 18 years) with clinically diagnosed retinitis pigmentosa (RP) or other similar degenerative retinal disease * Current treatment with TES using the OkuStim® System within the intended purpose * Subjective perception of short-term effects after TES treatment * Ability and willingness to give informed consent Exclusion Criteria: * Cognitive, psychological, or linguistic limitations that prevent informed consent or proper study participation * Presence of other eye diseases (e.g., cataract, glaucoma, macular degeneration) that, in the opinion of the investigator, compromise or confound study assessments * Simultaneous participation in other clinical studies that could influence the results of the study * Severe comorbidities that could compromise patient safety or study conduct
Contact & Investigator
Dr. med. Svenja Deuchler
PRINCIPAL INVESTIGATOR
Augenzentrum Frankfurt Prof. Koch GmbH
Frequently Asked Questions
Who can join the NCT07548944 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Retinitis Pigmentosa (RP). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07548944 currently recruiting?
Yes, NCT07548944 is actively recruiting participants. Contact the research team at info@azffm.de for enrollment information.
Where is the NCT07548944 trial being conducted?
This trial is being conducted at Frankfurt am Main, Germany.
Who is sponsoring the NCT07548944 clinical trial?
NCT07548944 is sponsored by Okuvision GmbH. The principal investigator is Dr. med. Svenja Deuchler at Augenzentrum Frankfurt Prof. Koch GmbH. The trial plans to enroll 30 participants.